重视中成药在哮喘防治中的规范化应用OA北大核心CSTPCD
Standardized Application of Chinese Patent Medicine in Treatment of Asthma:Interpretation of the Clinical Application Guidelines of Chinese Patent Medicine for Adults with Bronchial Asthma(2021)
中成药防治支气管哮喘积累了丰富的理论与实践经验,但多数中成药的疗效、安全性、应用指征、作用特点等尚不明确,导致不合理、不规范使用现象广泛存在.基于循证的有效性与安全性证据,明确中成药的适应症,规范中成药的使用并制定合理化治疗策略是发挥中成药优势的关键.在此背景下,国家中医药管理局首部基于循证的《中成药治疗成人支气管哮喘临床应用指南》于2022年3月正式发布.本文结合指南编写过程、临床经验,从指南编写过程、推荐意见对指南进行解读,探讨中成药在哮喘防治中的临床价值与特色,并指出本领域未来的研究方向.
Chinese patent medicine(CPM)has been applied to the treatment of asthma widely and built up richer theoretical and practical experience.However,the clinical application of CPM still suffers from unclear efficacy,safety,application indications,and function characteristics,leading to unreasonable and non-standard usage.Evidence-based effectiveness and safety,the full description of instruction including dosage,course,target user,and usage basing syndrome differentiation are the keys to maximizing the curative effect of CPM.In this context,the National Administration of Traditional Chinese Medicine approved the first evidence-based guideline of Clinical Application Guidelines of CPM for Adults with Bronchial Asthma was released in March 2022.Based on the methodology of guidelines and clinical experience,this paper clarifies the particularity and value of CPM in the management of asthma and put forward the research direction.
王建新;林江涛;孙增涛;张洪春;苗青;李秋爽;杨佳慧;孙媛媛
中国中医科学院西苑医院临床药理研究所(北京 100091)||中国中医科学院博士后流动站(北京 100700)中日友好医院呼吸中心(北京 100029)天津中医药大学第二附属医院呼吸科(天津 300150)中国中医科学院西苑医院临床药理研究所(北京 100091)《中成药治疗优势病种临床应用指南》标准化项目组(北京 100061)||中国中药协会标准化项目管理办公室(北京 100061)
哮喘中成药指南解读
asthmaChinese patent medicineguidelinesinterpretation
《中国中西医结合杂志》 2024 (012)
1514-1519 / 6
国家中医药管理局《中成药治疗优势病种临床应用指南》标准化项目(No.SATCM-2015-BZ402);中国中医科学院科技创新工程重大攻关项目(No.CI2021A04701)
评论